World Congress on

Bioavailability & Bioequivalence: BA/BE Studies Summit

Tokyo, Japan    August 06-07, 2018

Theme: BA/BE: Essential Innovation in Contemporary Studies

Meeting international proudly announces the World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit” which will be held during August 06-07, 2018 at Tokyo, Japan The theme of conference is BA/BE: Essential Innovation in Contemporary Studies. Meetings International provides a Global Platform for Pharmacologist, Healthcare Professionals, Bioinformatics, Clinical and Cellular Pharmacologists and Biotech Professionals to Exchange Ideas, Knowledge and Networking at its World Conferences.

BABE 2018 mainly focuses on Bioavailability & Bioequivalence for pharmacopoeia, in the hands of clinical investigators, provide a dynamic and powerful approach to understanding the spectrum of drug development with obvious applications in Drug discovery, Pharmacogenomics, Clinical trials , Pharmacokinetics and Pharmacology and Computer-aided drug design, diagnosis, and disease management. Historically, the development of perceptive and precise bio analytical approach in the 1960s and 1970s was allowed for the first time, the measurement of very low levels of drug concentrations in biological fluids. Correspondingly, pharmacokinetic profiles of drugs, describing absorption, distribution, and clearance, could be determined. Regulations related to bioavailability and bioequivalence were put into place, considering the latest advances in the science. A significant role in the discovery, development, and regulation of new drug products involves in recent research of Bioavailability and Bioequivalence. a crucial component of abbreviated new drug applications (ANDAs), leading to market access of safe, effective, and low cost in the advance studies of bioequivalence

Why to attend??

With members from around the world focused on learning about Bioavailability & Bioequivalence: BA/BE Studies and its advances; this is your best opportunity to reach the largest assemblage of participants from the Pharmaceuticals, drug developer and its allied areas. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new Development of BABE Studies, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in BABE studies are hallmarks of this conference.

Bioavailability and Bioequivalence conference | Pharmaceutics & Novel Drug Delivery Systems Conference | Drug Discovery, Designing and Development Conference | Pharmacy and Pharmaceutical Sciences Conference

Track 1: Emerging Bioavailability & Bioequivalence studies

Historically, the development of perceptive and precise bio analytical approach in the 1960s and 1970s was allowed for the first time, the measurement of very low levels of drug concentrations in biological fluids. Correspondingly, pharmacokinetic profiles of drugs, describing absorption, distribution, and clearance, could be determined. Regulations related to bioavailability and bioequivalence were put into place, considering the latest advances in the science. A significant role in the discovery, development, and regulation of new drug products involves in recent research of Bioavailability and Bioequivalence. A crucial component of abbreviated new drug applications (ANDAs), leading to market access of safe, effective, and low cost in the advance studies in bioequivalence conference

Related Conferences: 

5th Chemistry in Drug Discovery & Designing congress April 16-17, 2018 Japan; Medicinal and Pharmaceutical Chemistry conference July 19-21, 2018 Japan; 16th Pharmaceutics & Novel Drug Delivery Systems Conference March 19-21, 2018 Berlin, Germany; 15th European Pharma Congress, May 07-09, 2018 Frankfurt, Germany

Related Societies and Associations

Generic Pharmaceutical Association ; US Food and Drug Administration( FDA) , USA; European Generic medicines Association, Europe; Therapeutics Goods Administration (TGA), UAE;  European Economic Area, Europe;  Canadian Generic Pharmaceutical Association (CGPA),Canada ; Bioequivalence and Bioavailability forum , Japan ;  FDA Office of Surveillance and Epidemiology, USA ; American Association for Clinical Chemistry (AACC), USA ; American Association of Pharmaceutical Scientists (AAPS), USA; Clinical Trials Information from National Institutes for Health (NIH), USA; National Institute of Standards and Technology (NIST),USA;

Track 2: Advances in BA&BE

Bioavailability and bioequivalence conference is a platform to have all the scientific eminent across the globe. In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

Related Conferences;

4th Drug Discovery, Designing and Development Conference June 27-28, 2018 Vancouver, Canada ; Pharmaceutical & Pharmacological Research Conference, March 28-29, 2018 Japan; Global Pharma Meet & Expo February 26-28, 2018 Japan; Pharmaceutics & Novel Drug Delivery Systems conference ,December 11-13, 2017 Japan; Pharmaceutical conference and expo March 21-23, 2018 Philadelphia, USA; Pharma Conference and Expo May 2-4, 2018 ; Rome, Italy.

Related Societies and Associations:

 International Society of Pharmaceutical Compounding (ISPhC), USA;  International Young Pharmacists' Group (YPG), USA; Parenteral Drug Association (PDA),  Japan; Regulatory Affairs Professionals Society (RAPS), USA;  Society for Bio molecular Sciences (SBA), USA; Society for Cell Science (SFCS), USA; Al-Hayat Pharmaceuticals, USA;  Amgen, Europe;  Elis Pharmaceuticals Limited, Japan;  Alliance Global, Japan; Sanofi Aventis UAE , UAE; Genpharm, UAE; Ranbaxy Laboratories Limited, USA; BioPharma, Japan; Hokkaido University , USA; Waseda University ,UAE; Nagoya University, UAE

Track 3:  BA/BE of Biologic & Biosimilar

Biologic & Biosimilar conference is a platform to have all the scientific eminent across the globe. The bio similar segment is one of the fastest growing segments and is likely to reach more than USD 25 billion by 2020.  Despite high development costs, the bio similar segment is likely to witness rapid growth due to the rising number of off-patent biologic drugs. The growth of this sector is attributed to the positive outcomes of on-going clinical trials and the growing demand for bio similar in different therapeutic applications. The application of advanced technologies such as recombinant DNA technology, genetic engineering, and combinatorial chemistry has increased the entry of novel biopharmaceuticals in the market which will contribute to this segment’s growth over the next four years.

Related Conference : 

Pharmaceutical Chemistry and Drug Design conference, September 3-5, 2018 Japan; Molecular Biology and Medicine conference, August 27-28, 2018 Japan; Advanced Materials Science & Nano Technology conference, August 27-29, 2018 Japan; 2nd Generic Drugs and Biosimilars Conference December 14-15, 2017 Rome, Italy; 12th Pharmaceutical Sciences and Innovations in Pharma Industry Congress February 26- 27, 2018 London, UK 

Related Societies and Associations

Generic Pharmaceutical Association ; US Food and Drug Administration( FDA) , USA; European Generic medicines Association, Europe; Therapeutics Goods Administration (TGA), UAE;  European Economic Area, Europe;  Canadian Generic Pharmaceutical Association (CGPA),Canada ; Bioequivalence and Bioavailability forum , Japan ;  FDA Office of Surveillance and Epidemiology, USA ; American Association for Clinical Chemistry (AACC), USA ; American Association of Pharmaceutical Scientists (AAPS), USA; Clinical Trials Information from National Institutes for Health (NIH), USA; National Institute of Standards and Technology (NIST), USA;

Track 4: Challenges in Drug Design and development

Drug discovery conference is a platform to have all the scientific eminent across the globe. This process basically is a patient oriented science, where researchers strive to improve the existing drugs or invent a totally new chemical entity, which should be ideally more potent than any existing drug of a similar category. If not, then at least it should be safer than those existing. This process is a very time consuming and expensive activity, calling for the expertise of many eminent researchers. It takes nearly 12-14 years of exhaustive research and a huge amount of financial investment for the discovery of a single drug

Related Conferences;

16th Pharmaceutics & Novel Drug Delivery Systems Conference March 19-21, 2018 Berlin, Germany; Dubai International Pharmaceuticals and Technologies Conference  February 27-March 1 Japan; Global Pharma Meet April 02-04, 2018, Dubai; 11th Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology Meeting March 19- 22  2018 Granada, Spain; 20th Pharmacy and Pharmaceutical Sciences Conference February 15 - 16, 2018 London, United Kingdom; 11th Pharmacovigilance Conference 24 January 2018 London , UK

Related Societies and Associations

International Society of Pharmaceutical Compounding (ISPhC), USA;  International Young Pharmacists' Group (YPG), USA; Parenteral Drug Association (PDA),  Japan; Regulatory Affairs Professionals Society (RAPS), USA;  Society for Bio molecular Sciences (SBA),USA; Society for Cell Science (SFCS), USA; Al-Hayat Pharmaceuticals, USA;  Amgen, Europe;  Elis Pharmaceuticals Limited, Japan;  Alliance Global, Japan; Sanofi Aventis UAE , UAE; Genpharm, UAE; Ranbaxy Laboratories Limited, USA; BioPharma, Japan; Hokkaido University , USA; Waseda University ,UAE; Nagoya University, UAE

Track 5: Natural products in drug discovery and development

Bioavailability is one of the essential tools in Pharmacokinetics, as bioavailability must be considered when calculating dosages for no intravenous routes of administration. An appropriate BE method often needs to be established based on a scientific analysis of each drug product. The above was a brief overview of bioavailability study protocol with some of its specification and essential features. Bioavailability or Bioequivalence which is actually the heart and soul of therapeutic response of a drug moiety in a given drug product.

Related Conferences;

5th Chemistry in Drug Discovery & Designing congress April 16-17, 2018 Japan; Medicinal and Pharmaceutical Chemistry conference July 19-21, 2018 Japan; 16th Pharmaceutics & Novel Drug Delivery Systems Conference March 19-21, 2018 Berlin, Germany; 15th European Pharma Congress, May 07-09, 2018 Frankfurt, Germany

Related Societies and Associations

Generic Pharmaceutical Association ; US Food and Drug Administration( FDA) , USA; European Generic medicines Association, Europe; Therapeutics Goods Administration (TGA), UAE;  European Economic Area, Europe;  Canadian Generic Pharmaceutical Association (CGPA),Canada ; Bioequivalence and Bioavailability forum , Japan ;  FDA Office of Surveillance and Epidemiology, USA ; American Association for Clinical Chemistry (AACC),USA ; American Association of Pharmaceutical Scientists (AAPS), USA; Clinical Trials Information from National Institutes for Health (NIH), USA; National Institute of Standards and Technology (NIST), USA;

Track 6: Bioequivalence Protocol: in-vitro / in-vivo studies

Human pharmacokinetic conference is a platform to have all the scientific eminent across the globe. Human pharmacokinetic in vivo studies are often presumed to serve as the “gold standard” to assess product bioequivalence (BE) of immediate-release (IR) solid oral dosage forms. However, when this general assumption is re-visited, it appears that in vitro studies are sometimes better than in vivo studies in assessing BE of IR solid oral dosage forms. Reduced costs are achieved through avoiding in vivo studies where BE is self-evident, where biopharmaceutical data anticipates BE, and where in vivo BE study type II error is high. Sponsors of potential in vivo human pharmacokinetic BE testing should be required to justify why in vitro data is insufficient, similar to proposed animal testing requires justification to not employ an in vitro approach.

Related Conferences;

4th Drug Discovery, Designing and Development Conference June 27-28, 2018 Vancouver, Canada ; Pharmaceutical & Pharmacological Research Conference, March 28-29, 2018 Japan; Global Pharma Meet & Expo February 26-28, 2018 Japan; Pharmaceutics & Novel Drug Delivery Systems conference ,December 11-13, 2017 Japan; Pharmaceutical conference and expo March 21-23, 2018 Philadelphia, USA; Pharma Conference and Expo May 2-4, 2018 ; Rome, Italy.

Related Societies and Associations:

 International Society of Pharmaceutical Compounding (ISPhC), USA;  International Young Pharmacists' Group (YPG), USA; Parenteral Drug Association (PDA),  Japan; Regulatory Affairs Professionals Society (RAPS), USA;  Society for Bio molecular Sciences (SBA),USA; Society for Cell Science (SFCS), USA; Al-Hayat Pharmaceuticals, USA;  Amgen, Europe;  Elis Pharmaceuticals Limited, Japan;  Alliance Global, Japan; Sanofi Aventis UAE , UAE; Genpharm, UAE; Ranbaxy Laboratories Limited, USA; BioPharma, Japan; Hokkaido University , USA; Waseda University ,UAE; Nagoya University, UAE

Track 7: Bio pharmaceutics Applications & Clinical pharmacology

Drug product conference performance is a vital aspect of drug development as it draws on interdisciplinary expertise from both pharmaceutics and pharmacokinetics disciplines. It is at the key interface that the discipline of bio pharmaceutics has emerged. The past two decades have witnessed considerable advances in bio pharmaceutics particularly with regard to bioavailability and bioequivalence, as they relate to product quality and regulatory standards of approval.

Related Conferences;

Pharmaceutical Chemistry and Drug Design conference, September 3-5, 2018 Japan; Molecular Biology and Medicine conference, August 27-28, 2018 Japan; Advanced Materials Science & Nano Technology conference, August 27-29, 2018 Japan; 2nd Generic Drugs and Biosimilars Conference December 14-15, 2017 Rome, Italy; 12th Pharmaceutical Sciences and Innovations in Pharma Industry Congress February 26- 27, 2018 London, UK

Related Societies and AssociationsGeneric Pharmaceutical Association ; US Food and Drug Administration( FDA) , USA; European Generic medicines Association, Europe; Therapeutics Goods Administration (TGA), UAE;  European Economic Area,  Europe;  Canadian Generic Pharmaceutical Association (CGPA), Canada ; Bioequivalence and Bioavailability forum , Japan ;  FDA Office of Surveillance and Epidemiology, USA ; American Association for Clinical Chemistry (AACC), USA ; American Association of Pharmaceutical Scientists (AAPS), USA; Clinical Trials Information from National Institutes for Health (NIH), USA; National Institute of Standards and Technology (NIST), USA;

Track 8: Regulatory Policies, procedure and prerequisites for clinical Research

Failure at any stage would mean a huge loss for the company. Hence, a lot of planning is required even before the project is underway. Recently, with the use of technology the process is becoming a less risky business, because of the ability of the computers to predict the possible outcomes. This will surely reduce the efforts in fruitless directions. Hence, the most important and most common biological targets for drug discovery are either enzymes regulating the biochemistry or the receptors through which many hormones and endogenous effectors show their response.

Related Conferences;

16th Pharmaceutics & Novel Drug Delivery Systems Conference March 19-21, 2018 Berlin, Germany; Dubai International Pharmaceuticals and Technologies Conference  February 27-March 1 Japan; Global Pharma Meet April 02-04, 2018, Dubai; 11th Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology Meeting March 19- 22  2018 Granada, Spain; 20th Pharmacy and Pharmaceutical Sciences Conference February 15 - 16, 2018 London, United Kingdom; 11th Pharmacovigilance Conference 24 January 2018 London , UK

Related Societies and Associations

International Society of Pharmaceutical Compounding (ISPhC), USA;  International Young Pharmacists' Group (YPG), USA; Parenteral Drug Association (PDA),  Japan; Regulatory Affairs Professionals Society (RAPS), USA;  Society for Bio molecular Sciences (SBA),USA; Society for Cell Science (SFCS), USA; Al-Hayat Pharmaceuticals, USA;  Amgen, Europe;  Elis Pharmaceuticals Limited, Japan;  Alliance Global, Japan; Sanofi Aventis UAE , UAE; Genpharm, UAE; Ranbaxy Laboratories Limited, USA; BioPharma, Japan; Hokkaido University , USA; Waseda University ,UAE; Nagoya University, UAE

Track 9: Bioavailability of a nutrient

Nutrient Bioavailability conference is a platform to have all the scientific eminent across the globe. The proportion of a nutrient that is absorbed from the diet and used for normal body functions is termed as nutrient bioavailability. Nutrient bioavailability may vary from one person to the next. Two different people can consume the exact same nutrient in the exact same form, yet their bodies may absorb and use different quantities of that nutrient. Because bioavailability is heavily dependent upon the digestive process, a digestive system operating at less than optimal efficiency may not be, and probably isn’t, able to fully absorb and use all the nutrients it encounters.

Related Conferences;

5th Chemistry in Drug Discovery & Designing congress April 16-17, 2018 Japan; Medicinal and Pharmaceutical Chemistry conference July 19-21, 2018 Japan; 16th Pharmaceutics & Novel Drug Delivery Systems Conference March 19-21, 2018 Berlin, Germany; 15th European Pharma Congress, May 07-09, 2018 Frankfurt, Germany

Related Societies and Associations

Generic Pharmaceutical Association ; US Food and Drug Administration( FDA) , USA; European Generic medicines Association, Europe; Therapeutics Goods Administration (TGA), UAE;  European Economic Area, Europe;  Canadian Generic Pharmaceutical Association (CGPA), Canada ; Bioequivalence and Bioavailability forum , Japan ;  FDA Office of Surveillance and Epidemiology, USA ; American Association for Clinical Chemistry (AACC), USA ; American Association of Pharmaceutical Scientists (AAPS), USA; Clinical Trials Information from National Institutes for Health (NIH), USA; National Institute of Standards and Technology (NIST), USA;

Track 10: Food-Effect Bioavailability and Fed Bioequivalence Studies

This guidance provides recommendations to sponsors and/or applicants planning to conduct food-effect bioavailability (BA) and fed bioequivalence (BE) studies for orally administered drug products as part of investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplements to these applications. This guidance applies to both immediate-release and modified-release drug products. Food-effect BA studies should be conducted early in the drug development process to guide and select formulations for further development. Food-effect BA information should be available to design clinical safety and efficacy studies and to provide information for the clinical pharmacology and/or dosage and administration sections of product labels.

Related Conferences;

4th Drug Discovery, Designing and Development Conference June 27-28, 2018 Vancouver, Canada ; Pharmaceutical & Pharmacological Research Conference, March 28-29, 2018 Japan; Global Pharma Meet & Expo February 26-28, 2018 Japan; Pharmaceutics & Novel Drug Delivery Systems conference ,December 11-13, 2017 Japan; Pharmaceutical conference and expo March 21-23, 2018 Philadelphia, USA; Pharma Conference and Expo May 2-4, 2018 ; Rome, Italy.

Related Societies and Associations:

 International Society of Pharmaceutical Compounding (ISPhC), USA;  International Young Pharmacists' Group (YPG), USA; Parenteral Drug Association (PDA),  Japan; Regulatory Affairs Professionals Society (RAPS), USA;  Society for Bio molecular Sciences (SBA),USA; Society for Cell Science (SFCS), USA; Al-Hayat Pharmaceuticals, USA;  Amgen, Europe;  Elis Pharmaceuticals Limited, Japan;  Alliance Global, Japan; Sanofi Aventis UAE , UAE; Genpharm, UAE; Ranbaxy Laboratories Limited, USA; BioPharma, Japan; Hokkaido University , USA; Waseda University ,UAE; Nagoya University, UAE

Track 11: Market of generic drugs

The global generic drugs market meet will grow at an impressive CAGR of more than 10% over the forecast period. With many pharmaceutical drugs set to lose their patents during the forecast period, the competition in the generic medications market is expected to increase in the coming years. Patent expiry of a branded drug results in the introduction of inexpensive generic drugs in the market.

Related Conferences;

Pharmaceutical Chemistry and Drug Design conference, September 3-5, 2018 Japan; Molecular Biology and Medicine conference, August 27-28, 2018 Japan; Advanced Materials Science & Nano Technology conference, August 27-29, 2018 Japan; 2nd Generic Drugs and Biosimilars Conference December 14-15, 2017 Rome, Italy; 12th Pharmaceutical Sciences and Innovations in Pharma Industry Congress February 26- 27, 2018 London, UK 

Related Societies and Associations

Generic Pharmaceutical Association ; US Food and Drug Administration( FDA) , USA; European Generic medicines Association, Europe; Therapeutics Goods Administration (TGA), UAE;  European Economic Area, Europe;  Canadian Generic Pharmaceutical Association (CGPA), Canada ; Bioequivalence and Bioavailability forum , Japan ;  FDA Office of Surveillance and Epidemiology, USA ; American Association for Clinical Chemistry (AACC), USA ; American Association of Pharmaceutical Scientists (AAPS), USA; Clinical Trials Information from National Institutes for Health (NIH), USA; National Institute of Standards and Technology (NIST), USA;

Track 12: Clinical errors and Entrepreneur unify

The decision to terminate a trial early due to unacceptable toxicity or substantial and convincing evidence of benefit is complex and must account for many factors These include possible imbalances in risk factors between treatment groups, whether the patients have the risk profile assumed in the design, patient compliance to therapy, quality and timeliness of data, possible sources of bias, consistency of primary and secondary outcome variables, the benefit-to-risk ratio, consistency of results with external data, and the impact of early termination on the medical community as well as the public. Evaluation of these issues goes beyond routine statistical tests and requires the collective judgment of experts, such as those represented by a DSMB. For decades the creation of new medicines has increased quality and quantity of life for patients around the globe.

Related Conferences;

16th Pharmaceutics & Novel Drug Delivery Systems Conference March 19-21, 2018 Berlin, Germany; Dubai International Pharmaceuticals and Technologies Conference  February 27-March 1 Japan; Global Pharma Meet April 02-04, 2018, Dubai; 11th Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology Meeting March 19- 22  2018 Granada, Spain; 20th Pharmacy and Pharmaceutical Sciences Conference February 15 - 16, 2018 London, United Kingdom; 11th Pharmacovigilance Conference 24 January 2018 London , UK

Related Societies and Associations

International Society of Pharmaceutical Compounding (ISPhC), USA;  International Young Pharmacists' Group (YPG), USA; Parenteral Drug Association (PDA),  Japan; Regulatory Affairs Professionals Society (RAPS), USA;  Society for Bio molecular Sciences (SBA),USA; Society for Cell Science (SFCS), USA; Al-Hayat Pharmaceuticals, USA;  Amgen, Europe;  Elis Pharmaceuticals Limited, Japan;  Alliance Global, Japan; Sanofi Aventis UAE , UAE; Genpharm, UAE; Ranbaxy Laboratories Limited, USA; BioPharma, Japan; Hokkaido University , USA; Waseda University ,UAE; Nagoya University, UAE

 

Introduction

The pharmaceutical industry is comprised of companies engaged in researching, developing, manufacturing and distributing drugs for human or veterinary use. New drugs have an enormous positive influence on global health, prosperity and economic productivity by saving lives, increasing life spans, reducing suffering, preventing surgeries and shortening hospital stays. Advances in medicine have eliminated deadly diseases and have brought other life-threatening conditions under control. Drug therapy is now an integral part of nearly every facet of healthcare, and new breakthroughs promise to revolutionize the treatment of non-communicable diseases.

Industry Overview and Competitiveness:

Large, diversified and global, the U.S. pharmaceutical industry is one of the most critical and competitive sectors in the economy. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), more than 810,000 people work in the biopharmaceutical industry in the United States across a broad range of occupations, such as scientific research, technical support and manufacturing. Directly and indirectly, the industry supports over 3.4 million jobs across the United States and added an estimated $790 billion to the economy in 2014. Although manufacturing jobs supported by the industry are expected to decline over the next decade due to continued productivity gains, it will remain an important source of high paying jobs, providing salaries way above the national average.

Research and development (R&D)

 The pharmaceutical sector has consistently been one of the most R&D intensive industries in the United States. The research-based industry generally allocates around 15 to 20 per cent of revenues to R&D activities and invests over $50 billion on R&D annually. Although the United States remains the global leader in innovative R&D investment, producing more than half the world’s new molecules in the last decade, its continued leadership cannot be taken for granted. R&D performed in the United States has become increasingly expensive relative to emerging economies in Asia, such as China and Singapore, where governments have enacted policies to attract investment and are poised for future growth. Conditions that limited R&D offshoring in the past, such as market proximity and availability of talent, are rapidly shifting.

The worldwide market for pharmaceuticals is projected to grow from around $1 trillion in 2015 to $1.3 trillion by 2020, representing an annual growth rate of 4.9 per cent. Several global demographic and economic trends are driving pharmaceutical consumption, including a rapidly aging world population and an associated rise in chronic diseases, increased urbanization and higher disposable incomes, greater government expenditure on healthcare and growing demand for more effective treatments.

Societies/Industries/Universities Associated with Pharmaceutical Technology and Development:-

  • International Society of Pharmaceutical Compounding (ISPhC)
  • International Young Pharmacists' Group (YPG)
  • Parenteral Drug Association (PDA)
  • Regulatory Affairs Professionals Society (RAPS)
  • Society for Bio molecular Sciences (SBA)
  • Society for Cell Science (SFCS)
  • Al-Hayat Pharmaceuticals      
  • Amgen
  • Elis Pharmaceuticals Limited 
  • Alliance Global
  • Sanofi Aventis UAE  
  • Genpharm
  • Ranbaxy Laboratories Limited
  • BioPharma
  • Hokkaido University
  • Waseda University
  • Nagoya University

Major Pharmaceutical Associations around the Globe

  • Bio analytical Focus Group and Ligand Binding Assay
  • American Association of Pharmaceutical Scientists (AAPS)
  • Royal Netherlands Chemical Society
  • The European Bio analysis Forum
  • BEBAC Consultancy Services for Bioequivalence and Bioavailability
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Generics and Bio similar Medicines Association (EGA)
  • Canadian Generic Pharmaceutical Association (CGPA)
  • Bioequivalence and Bioavailability forum
  • Generic Pharmaceutical Association (GPhA)
  • Pharmaceutical Management Agency (PHARMAC)
  • FDA Office of Surveillance and Epidemiology
  • Drug Watch
  • ORPHANET Parenteral Drug Association
  • PharmGKB
  • US Food and Drug Administration (FDA)
  • American Association for Clinical Chemistry (AACC)
  • American Association of Pharmaceutical Scientists (AAPS)
  • Clinical Trials Information from National Institutes for Health (NIH)
  • National Institute of Standards and Technology (NIST)
  • Association of the British Pharmaceutical Industry (ABPI)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Innovative Medicines Canada

Why in Japan???
Japan has a large, well-developed pharmaceutical market and offers universal health coverage to its citizens. However its traditional low-cost healthcare model is now trending towards other developed countries. In the absence of major healthcare reforms Japan will experience a funding gap of ¥19.2 trillion (~ $160 billion) by 2020 which is expected to rise to ¥44.2 trillion (~ $370 billion) by 2035. Increasing insurance premiums to fund the gap will increase labour costs and harm Japan’s competitive position. Co-payment rates are already high at 30%, and an additional increase would undermine the concept of health insurance.3–5 So, Japan needs alternative financial options.

Despite flat economic growth, Japan’s position in world pharmaceutical sales is projected to remain significant. The market in Japan is projected to grow 17% over the period 2011–2020 (based on constant exchange rates).Without a doubt, Japan Health Authority is attempting to build up the medicinal tourism part, expecting to draw in 1.3 million restorative visitors yearly by 2021. The revenue on medicinal tourism is required to develop by 13% every year for the following five years. The growth opportunities outside of Japan and the developed markets are significant for those companies who are poised to access them.

  • Emerging Bioavailability & Bioequivalence studies
  • Advances in BA&BE
  • BA/BE of Biologic & Biosimilar
  • Challenges in Drug Design and Development
  • Natural Products in Drug Discovery and Development
  • Bioequivalence Protocol: In-Vitro / In-Vivo Studies
  • Biopharmaceutics Applications & Clinical Pharmacology
  • Regulatory Policies, Procedure and Prerequisites for Clinical Research
  • Bioavailability of a Nutrient
  • Food-Effect Bioavailability and Fed Bioequivalence Studies
  • Market of Generic Drugs
  • Entrepreneur Unify and Clinical Errors

1 Organizing Committee Members

Media Partners & Collaborations

  • Media Partner

  • Media Partner